Apollomics Inc., a biopharmaceutical company based in the Cayman Islands with operations in the United States and China, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units for sale to the public. The registration statement includes a preliminary prospectus detailing the company's business, financials, and the risks associated with investing in its securities. Apollomics Inc. has not specified the amount of securities to be offered or the prices at which they will be sold. The securities may be sold from time to time in one or more offerings...Show More

Apollomics Inc., a biopharmaceutical company based in the Cayman Islands with operations in the United States and China, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units for sale to the public. The registration statement includes a preliminary prospectus detailing the company's business, financials, and the risks associated with investing in its securities. Apollomics Inc. has not specified the amount of securities to be offered or the prices at which they will be sold. The securities may be sold from time to time in one or more offerings, and the terms of these offerings will be determined at the time of sale. The company's Class A Ordinary Shares and warrants are currently listed on the Nasdaq Capital Market under the symbols 'APLM' and 'APLMW,' respectively. The registration statement indicates that Apollomics Inc. is an emerging growth company and a foreign private issuer, which exempts it from certain U.S. reporting requirements. The company has also highlighted the risks associated with its operations in China, including government control over currency conversion and potential difficulties in enforcing U.S. judgments in Chinese courts.